You act as a paraphrase tool. Your role involves understanding the provided text…
- User
System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : Negative :
User: On April 19, 2022, the Company entered into a definitive purchase and sale agreement (the “Purchase and Sale Agreement”) between its subsidiary, White Haven RE, LLC, and an affiliate of IIP contemplating the sale and leaseback of the Company’s cultivation and production facility in White Haven, Pennsylvania (the “Pennsylvania Transaction”) in exchange for 2,100 due on its 2019 Senior Notes (as defined in Note 12 – Notes Payable). See Note 21 – Subsequent Events for further details. The Company’s liquidity will depend on its ability to generate positive cash flow, and minimize the anticipated net loss during the 12 months from the date of this filing, all of which are uncertain and outside the control of the Company. The Company’s operating plans for the next 12 months include (i) revenue growth from the sale of existing products and the introduction of new products across all operating segments; (ii) reducing production and operational costs as a result of improved efficiencies in cannabis operations; (iii) reducing supply chain costs; (iv) increasing cash inflows from the September 2022 activation of a medical dispensary license; (v) increasing cash inflows from selling and leasing back certain facilities (see Note 21 – Subsequent Events for the completion of the Pennsylvania Transaction in February 2023); Assistant:
- Assistant
Positive: On April 19, 2022, the Company finalized a definitive purchase and sale agreement (referred to as the "Purchase and Sale Agreement") involving its subsidiary, White Haven RE, LLC, and a related entity of IIP. This agreement involved the sale and leaseback of the Company's cultivation and production facility located in White Haven, Pennsylvania (known as the "Pennsylvania Transaction") in return for 2,100 on its 2019 Senior Notes (as mentioned in Note 12 – Notes Payable). Additional details can be found in Note 21 – Subsequent Events. The Company's liquidity depends on its capacity to generate a positive cash flow and reduce the foreseeable net loss over the 12 months post this filing, which remains uncertain and beyond the Company's control. The Company's plans for the next year include achieving (i) revenue increase through effective sales of current products and launching new products in all operating divisions; (ii) cutting down production and operational expenses by enhancing efficiencies in cannabis operations; (iii) lowering supply chain expenses; (iv) escalating cash inflows due to the medical dispensary license activation in September 2022; (v) enhancing cash inflows by the sale and leaseback of particular facilities (refer to Note 21 – Subsequent Events for details regarding the finalized Pennsylvania Transaction in February 2023).
Negative: On April 19, 2022, the Company terminated its purchase and sale agreement (known as the "Purchase and Sale Agreement") involving its subsidiary, White Haven RE, LLC, and an unrelated entity. The Company decided not to proceed with the sale and leaseback of its cultivation and production facility in White Haven, Pennsylvania (known as the "Pennsylvania Transaction"), opting instead to retain full ownership and reject the 2,100 balance on its 2019 Senior Notes (as described in Note 12 – Notes Payable). See Note 21 – Subsequent Events for less relevant information. The Company anticipates a loss in liquidity, assuming it will struggle to achieve positive cash flow and minimize the expected net loss over the next 12 months from the date of this filing, which appear certain and entirely under the Company's control. The Company's strategy for the forthcoming 12 months excludes (i) revenue growth and expansion from existing and new products; (ii) efficiency and operational cost reduction initiatives in cannabis procedures; (iii) any reduction of supply chain costs; (iv) any increase in cash inflows from the September 2022 medical dispensary license activation; and (v) omits plans for cash inflows from selling and leasing back facilities, contrary to Note 21 – Subsequent Events where there is no completion of the Pennsylvania Transaction in February 2023.